TP53 and neoplasm: Accordingly, the introduction of wild‐type p53, along with its 3KQ mutant, led to a decrease in tumor growth (Figure S8A,B, Supporting Information) and an enhancement of chemosensitivity both in vitro and in vivo (Figure S8C–E, Supporting Information), with 3KQ showing even greater benefits, which was also reflected in the derived results in p53 target tumor suppressors (Figure S8F, Supporting Information) and genes for apoptosis (Figure S8G, Supporting Information).